Pathologic consequences of increased angiotensin II activity

Area of Science:

• Molecular Medicine
• Pharmacology
• Cardiovascular Physiology

Background:

• The renin-angiotensin system (RAS) plays a crucial role in cardiovascular function and electrolyte balance.
• Angiotensin II (AII), a key peptide in the RAS, is also implicated in regulating cellular oncogenes and growth factors.
• RAS components are expressed in various organs, suggesting local peptide actions beyond the kidneys.

Purpose of the Study:

• To investigate alternative pathways for AII production and characterize novel angiotensin peptides.
• To explore the role of angiotensin-(1-7) in regulating AII activity via nitric oxide and prostaglandins.
• To assess the therapeutic potential of AII-receptor blockers in managing hypertension and related cardiovascular conditions.

Main Methods:

• Investigated local tissue renin-angiotensin activity and novel angiotensin peptide forms.
• Studied the mechanism of angiotensin-(1-7) in stimulating vasodilator prostaglandins and nitric oxide release.
• Utilized orally active AII-receptor blockers to test AII's role in essential hypertension.

Main Results:

• Identified novel angiotensin peptides counteracting AII's vasoconstrictor and proliferative effects.
• Demonstrated angiotensin-(1-7)'s role in modulating AII activity through vasodilatory pathways.
• Confirmed the utility of AII-receptor blockers in evaluating AII's contribution to hypertension.

Conclusions:

• The RAS has diverse local actions beyond the kidneys, involving peptides like angiotensin-(1-7).
• Targeting AII receptors with novel blockers presents a promising therapeutic strategy for hypertension and cardiovascular sequelae.
• Further research into local RAS components and receptor interactions can lead to improved treatments.